Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Shares Outstanding: 2019-2025

Historic Shares Outstanding for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Sep 2025 value amounting to $46.8 million.

  • 4D Molecular Therapeutics' Shares Outstanding fell 10.05% to $46.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.8 million, marking a year-over-year decrease of 10.05%. This contributed to the annual value of $45.8 million for FY2024, which is 6.31% up from last year.
  • As of Q3 2025, 4D Molecular Therapeutics' Shares Outstanding stood at $46.8 million, which was up 0.15% from $46.7 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Shares Outstanding high stood at $52.0 million for Q3 2024, and its period low was $26.7 million during Q1 2021.
  • Its 3-year average for Shares Outstanding is $45.6 million, with a median of $46.3 million in 2025.
  • In the last 5 years, 4D Molecular Therapeutics' Shares Outstanding spiked by 418.75% in 2021 and then fell by 10.05% in 2025.
  • 4D Molecular Therapeutics' Shares Outstanding (Quarterly) stood at $32.2 million in 2021, then increased by 1.25% to $32.6 million in 2022, then soared by 32.02% to $43.1 million in 2023, then climbed by 6.31% to $45.8 million in 2024, then decreased by 10.05% to $46.8 million in 2025.
  • Its Shares Outstanding was $46.8 million in Q3 2025, compared to $46.7 million in Q2 2025 and $46.3 million in Q1 2025.